Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara, Inc. (CERT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:40pm, Wednesday, 10'th Sep 2025
Certara, Inc. (NASDAQ:CERT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Fin
Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)
12:21pm, Tuesday, 09'th Sep 2025
Certara, Inc. (NASDAQ:CERT ) Baird Global Healthcare Conference 2025 September 9, 2025 10:15 AM EDT Company Participants William Feehery - CEO & Director John Gallagher - SVP, Principal Accounting Off
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
08:00am, Thursday, 04'th Sep 2025
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus.
Certara to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 02'nd Sep 2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the follow
Cerrado Gold Inc. (CRDOF) Q2 2025 Earnings Call Transcript
01:32pm, Monday, 25'th Aug 2025
Cerrado Gold Inc. (OTCQX:CRDOF) Q2 2025 Earnings Conference Call August 25, 2025 11:00 AM ET Company Participants Michael McAllister - Vice President of Investor Relations Mark Peter Brennan - CEO & C
Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript
10:24pm, Wednesday, 06'th Aug 2025
Certara, Inc. (NASDAQ:CERT ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants John E. Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer William F.
Certara (CERT) Q2 Revenue Jumps 12%
09:13pm, Wednesday, 06'th Aug 2025
Certara (CERT -3.35%), a leader in biosimulation software and Model-Informed Drug Development solutions, released its Q2 FY2025 earnings on August 6, 2025. The most notable news was a slight revenue b
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
07:01pm, Wednesday, 06'th Aug 2025
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Certara Reports Second Quarter 2025 Financial Results
04:15pm, Wednesday, 06'th Aug 2025
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
02:00am, Monday, 04'th Aug 2025
Certara today announced that the European Medicines Agency has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
04:15pm, Thursday, 31'st Jul 2025
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D.
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Wednesday, 30'th Jul 2025
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Friday, 11'th Jul 2025
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences
03:09am, Friday, 11'th Jul 2025
Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and gr
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
04:15pm, Wednesday, 09'th Jul 2025
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q
